FDA rejects diabetes drug alogliptin; Takeda gives few CRL details

Takeda Pharmaceutical’s (TYO:4502) diabetes drug alogliptin failed to secure U.S. Food and Drug Administration approval. The agency issued a complete response letter for new drug applications of…
Read the full story: MedCity News